Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

78
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

917
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
917
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

1.3K
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.3K
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

465
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
465
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

927
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
927

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A beginner's guide to the clinical approach and key concepts of glomerular disease: a mini review.

Asian biomedicine : research, reviews and news·2026
Same author

Added value of dynamic SPECT/CT after kidney transplantation using a 3D-ring CZT-based camera: a case report.

EJNMMI research·2026
Same author

Coxsackie A6 Virus Infection in a Kidney Transplant Recipient.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.

Personalized medicine·2026
Same author

Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives.

Heart failure reviews·2025
Same author

BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses.

Frontiers in immunology·2025
Same journal

Cold ischemia time exceeding 12 hours is a risk factor for delayed graft function and increased mortality in kidney transplant recipients within the eurotransplant senior program.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Delayed graft function and long-term outcomes after deceased donor kidney transplantation: insights from mate-kidney analysis.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Regulatory approach to manipulated organs in Europe: preserving human organs as non-commercial goods.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Can european law keep pace with biomedical innovation? The reinvention of transplantation regulation.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Sex-related differences in survival based on [<sup>18</sup>F]FDG PET/CT metabolic tumor volume after liver transplantation for colorectal liver metastases.

Transplant international : official journal of the European Society for Organ Transplantation·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K

Mycophenolate revisited.

Teun van Gelder1, Dennis A Hesselink

  • 1Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Transplant International : Official Journal of the European Society for Organ Transplantation
|March 12, 2015
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) are popular immunosuppressants. Despite therapeutic equivalence, avoid switching between generic mycophenolate formulations due to potential risks.

Keywords:
genericmycophenolate mofetilmycophenolic acidtherapeutic drug monitoringtransplantation

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

23.6K

Related Experiment Videos

Last Updated: Apr 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

23.6K

Area of Science:

  • Pharmacology and Transplant Medicine

Background:

  • Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) have been widely used immunosuppressants for two decades.
  • Patent expirations for MMF and upcoming expiration for EC-MPS increase the availability of generic formulations.
  • Mycophenolate demonstrates significant benefits compared to azathioprine in immunosuppressive therapy.

Purpose of the Study:

  • To review the reasons behind the widespread popularity of mycophenolate in clinical practice.
  • To discuss the therapeutic equivalence of MMF and EC-MPS.
  • To highlight potential risks associated with switching between different mycophenolate formulations.

Main Methods:

  • This study is a review of existing literature and clinical data on mycophenolate use.
  • Comparative analysis of mycophenolate efficacy and safety against azathioprine.
  • Discussion of pharmacokinetic and pharmacodynamic considerations for MMF and EC-MPS.

Main Results:

  • MMF and EC-MPS are therapeutically equivalent immunosuppressive agents.
  • Mycophenolate drugs are not classified as narrow therapeutic index drugs, but switching between generics requires caution.
  • The lack of novel immunosuppressive drugs suggests continued reliance on mycophenolate for transplant recipients.

Conclusions:

  • Mycophenolate remains a cornerstone first-line immunosuppressant in transplantation.
  • Careful consideration is needed when transitioning between innovator and generic mycophenolate products, or between different generic brands.
  • Further research is required to determine the relationship between mycophenolic acid exposure and the development of donor-specific anti-HLA antibodies.